Fulgent Genetics, Inc.
FLGTNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for FLGT. That does not mean none is planned.
Get an email about FLGT's next catalysts
Track Fulgent Genetics (FLGT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FID007 | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Frequently asked questions
What is in Fulgent Genetics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Fulgent Genetics, Inc.'s (FLGT) pipeline across Phase 2. Its lead program is FID007 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Fulgent Genetics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Fulgent Genetics, Inc. (FLGT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FLGT biotech catalysts?→
Add FLGT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Fulgent Genetics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.